Anteris Technologies Global Corp. reported net operating cash outflows of $59.3 million for the nine months ended September 30, 2025, reflecting increased clinical, regulatory, and manufacturing activities related to the PARADIGM Trial. For the three months ended September 30, 2025, research and development expenses were $16.8 million, and selling, general and administrative expenses were $5.8 million. The company held $9.1 million in cash and cash equivalents as of September 30, 2025. During the quarter, Anteris advanced its quality management system, expanded manufacturing capacity, and received regulatory approvals to commence the PARADIGM Trial in the U.S. and Denmark.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574679-en) on November 12, 2025, and is solely responsible for the information contained therein.